Post-acute-withdrawal syndrome explained

Synonyms:Post-withdrawal syndrome, protracted withdrawal syndrome, prolonged withdrawal syndromes
Field:Psychiatry, Toxicology

Post-acute-withdrawal syndrome should not be confused with Pervasive refusal syndrome.

Post-acute withdrawal syndrome (PAWS) is a hypothesized set of persistent impairments that occur after withdrawal from alcohol,[1] [2] opiates, benzodiazepines, antidepressants, and other substances.[3] [4] [5] Infants born to mothers who used substances of dependence during pregnancy may also experience a PAWS.[6] [7] While PAWS has been frequently reported by those withdrawing from opiate and alcohol dependence, the research has limitations. Protracted benzodiazepine withdrawal has been observed to occur in some individuals prescribed benzodiazepines.[8] [9]

Drug use, including alcohol and prescription drugs, can induce symptomatology which resembles mental illness. This can occur both in the intoxicated state and during the withdrawal state. In some cases these substance-induced psychiatric disorders can persist long after detoxification from amphetamine, cocaine, opioid, and alcohol use, causing prolonged psychosis, anxiety or depression. A protracted withdrawal syndrome can occur with symptoms persisting for months to years after cessation of substance use. Benzodiazepines, opioids, alcohol, and any other drug may induce prolonged withdrawal and have similar effects, with symptoms sometimes persisting for years after cessation of use. Psychosis including severe anxiety and depression are commonly induced by sustained alcohol, opioid, benzodiazepine, and other drug use which in most cases abates with prolonged abstinence. Any continued use of drugs or alcohol may increase anxiety, psychosis, and depression levels in some individuals. In almost all cases drug-induced psychiatric disorders fade away with prolonged abstinence, although permanent damage to the brain and nervous system may be caused by continued substance use.[10]

Signs and symptoms

Symptoms can sometimes come and go with wave-like re-occurrences or fluctuations in severity of symptoms. Common symptoms include impaired cognition, irritability, depressed mood, and anxiety; all of which may reach severe levels which can lead to relapse.[11] [12]

The protracted withdrawal syndrome from benzodiazepines, opioids, alcohol and other addictive substances can produce symptoms identical to generalized anxiety disorder as well as panic disorder. Due to the sometimes prolonged nature and severity of benzodiazepine, opioid and alcohol withdrawal, abrupt cessation is not advised.[13]

Hypothesized symptoms of PAWS are:[14] [15] [16] [17]

Symptoms occur intermittently, but are not always present. They are made worse by stress or other triggers and may arise at unexpected times and for no apparent reason. They may last for a short while or longer. Any of the following may trigger a temporary return or worsening of the symptoms of PAWS:

Post-acute benzodiazepine withdrawal

See also: Benzodiazepine withdrawal syndrome. Disturbances in mental function can persist for several months or years after withdrawal from benzodiazepines. Psychotic depression persisting for more than a year following benzodiazepine withdrawal has been documented in the medical literature. The patient had no prior psychiatric history. The symptoms reported in the patient included, major depressive disorder with psychotic features, including persistent depressed mood, poor concentration, decreased appetite, insomnia, anhedonia, anergia and psychomotor retardation. The patient also experienced paranoid ideation (believing she was being poisoned and persecuted by co-employees), accompanied by sensory hallucinations. Symptoms developed after abrupt withdrawal of chlordiazepoxide and persisted for 14 months. Various psychiatric medications were trialed which were unsuccessful in alleviating the symptomatology. Symptoms were completely relieved by recommending chlordiazepoxide for irritable bowel syndrome 14 months later.[19] Another case report noted a similar phenomenon in a female patient who abruptly reduced her diazepam dosage from 30 mg to 5 mg per day. She developed electric shock sensations, depersonalization, anxiety, dizziness, left temporal lobe EEG spiking activity, hallucinations, visual perceptual and sensory distortions which persisted for years.[20]

A clinical trial of patients taking the benzodiazepine alprazolam (Xanax) for eight weeks triggered protracted symptoms of memory deficits which were still present after up to eight weeks post cessation of alprazolam.[21]

Dopamine agonist protracted withdrawal

After long-term use of dopamine agonists, a withdrawal syndrome may occur during dose reduction or discontinuation with the following possible side effects: anxiety, panic attacks, dysphoria, depression, agitation, irritability, suicidal ideation, fatigue, orthostatic hypotension, nausea, vomiting, diaphoresis, generalized pain, and drug cravings. For some individuals, these withdrawal symptoms are short-lived and make a full recovery, for others a protracted withdrawal syndrome may occur with withdrawal symptoms persisting for months or years.[22]

Cause

The syndrome may be in part due to persisting physiological adaptations in the central nervous system manifested in the form of continuing but slowly reversible tolerance, disturbances in neurotransmitters and resultant hyperexcitability of neuronal pathways.[23] [24] [25] [26] However, data supports "neuronal and overwhelming cognitive normalization" in regards to chronic amphetamine use and PAWS.[27] [28] Stressful situations arise in early recovery, and the symptoms of post acute withdrawal syndrome produce further distress. It is important to avoid or to deal with the triggers that make post acute withdrawal syndrome worse. The types of symptomatology and impairments in severity, frequency, and duration associated with the condition vary depending on the drug of use.

Treatment

The condition gradually improves over a period of time which can range from six months to several years in more severe cases.[29] [30]

Flumazenil was found to be more effective than placebo in reducing feelings of hostility and aggression in patients who had been free of benzodiazepines for 4 to 266 weeks.[31] This may suggest a role for flumazenil in treating protracted benzodiazepine withdrawal symptoms.

Acamprosate has been found to be effective in alleviating some of the post acute withdrawal symptoms of alcohol withdrawal.[32] [33] Carbamazepine or trazodone may also be effective in the treatment of post acute withdrawal syndrome in regards to alcohol use.[34] [35] [36] Cognitive behavioral therapy can also help the post acute withdrawal syndrome especially when cravings are a prominent feature.[37]

See also

Notes and References

  1. Book: Stephen Rich J, Martin PR . Alcohol and the Nervous System . Co-occurring psychiatric disorders and alcoholism . Handb Clin Neurol . 125 . 573–88 . 2014 . 25307597 . 10.1016/B978-0-444-62619-6.00033-1 . Handbook of Clinical Neurology . 9780444626196 .
  2. Koob. George F.. 2009. Dynamics of Neuronal Circuits in Addiction: Reward, Antireward, and Emotional Memory. Pharmacopsychiatry. 42. Suppl 1. S32–S41. 10.1055/s-0029-1216356. 0176-3679. 2739305. 19434554.
  3. Book: Collier . Judith . Longmore . Murray . Peter . Scally . Oxford Handbook of Clinical Specialties . 6 . 2003 . Oxford University Press . 978-0-19-852518-9 . 366 . 4.
  4. J Subst Abuse Treat . 1991 . 8 . 1–2 . 19–28 . Protracted withdrawal syndromes from benzodiazepines . Ashton H . 1675688 . benzo.org.uk . 10.1016/0740-5472(91)90023-4 .
  5. Wu JM . Wei DY . Luo YF . Xiang XY . November 2003 . [Clinic research on heroin de-addiction effects of acupuncture and its potentiality of preventing relapse] . Zhong Xi Yi Jie He Xue Bao . 1 . 4 . 268–72 . 15339529 . 10.3736/jcim20030412 .
  6. Lejeune C . Floch-Tudal C . Montamat S . Crenn-Hebert C . Simonpoli AM . March 1997 . [Management of drug addict pregnant women and their children] . Arch Pediatr . 4 . 3 . 263–70 . 9181022 . 10.1016/S0929-693X(97)87247-8 .
  7. Gaillard MC . Borruat FX . April 2002 . [New finding: transitory horizontal pendular nystagmus secondary to neonatal abstinence syndrome] . Klin Monatsbl Augenheilkd . 219 . 4 . 317–9 . 12022028 . 10.1055/s-2002-30650 . 72584335 .
  8. Satel SL . American Journal of Psychiatry . Should protracted withdrawal from drugs be included in DSM-IV? . May 1993 . 150 . 5 . 695–704 . 8097618 . 10.1176/ajp.150.5.695.
  9. Ashton H. Protracted withdrawal syndromes from benzodiazepines. . J Subst Abuse Treat . 1991 . 8 . 1–2 . 19–28 . 1675688 . 10.1016/0740-5472(91)90023-4 .
  10. Book: Evans . Katie . Sullivan . Michael J. . Dual Diagnosis: Counseling the Mentally Ill Substance Abuser . 2nd . 1 March 2001 . Guilford Press . 978-1-57230-446-8 . 75–76 .
  11. Stojek A . Madejski J . Dedelis E . Janicki K . May–Jun 1990 . [Correction of the symptoms of late substance withdrawal syndrome by intra-conjunctival administration of 5% homatropine solution (preliminary report)] . Psychiatr Pol . 24 . 3 . 195–201 . 2084727 .
  12. Bokhan NA . Abolonin AF . Krylov EN . Vetlugina TP . Ivanova SA . 2003 . Comparative Efficiency of Proproten-100 during the Therapy of Patients with Alcoholism in the Stage of Therapeutic Remission . Bull Exp Biol Med . 135 . Suppl 1 . 171–5 . 12949690 . 10.1023/A:1024709014483 . 10798202 .
  13. Book: Riba . Michelle B. . Ravindranath . Divy . Clinical manual of emergency psychiatry . 12 April 2010 . American Psychiatric Publishing Inc . Washington, DC . 978-1-58562-295-5 . 197 .
  14. De Soto CB . O'Donnell WE . Allred LJ . Lopes CE . December 1985 . Symptomatology in alcoholics at various stages of abstinence . . 9 . 6 . 505–12 . 3911810 . 10.1111/j.1530-0277.1985.tb05592.x .
  15. Voltaire-Carlsson A . Hiltunen AJ . Koechling UM . Borg S . Sep–Oct 1996 . Effects of long-term abstinence on psychological functioning: a prospective longitudinal analysis comparing alcohol-dependent patients and healthy volunteers . Alcohol . 13 . 5 . 415–21 . 8888936 . 10.1016/0741-8329(96)81678-8 .
  16. Watanabe KI . Ogihara-Hashizume A . Kobayashi Y . Mitsushio H . Komiyama T . April 2001 . Impaired sleep during the post-alcohol withdrawal period in alcoholic patients . Addict Biol . 6 . 2 . 163–169 . 11341856 . 10.1080/13556210020040244 . 38350347 .
  17. Vik PW . Cellucci T . Jarchow A . Hedt J . March 2004 . Cognitive impairment in substance abuse . Psychiatr Clin North Am . 27 . 1 . 97–109 . 15062633 . 10.1016/S0193-953X(03)00110-2 .
  18. Janiri L . Martinotti G . Dario T . Reina D . Paparello F . Pozzi G . Addolorato G . Di Giannantonio M . De Risio S . June 3, 2005 . Anhedonia and substance-related symptoms in detoxified substance-dependent subjects: a correlation study . Neuropsychobiology . 52 . 1 . 37–44 . 15942262 . 10.1159/000086176 . 22464794 .
  19. Psychosomatics . Mar–Apr 1997 . 38 . 2 . 160–1 . Protracted benzodiazepine withdrawal syndrome mimicking psychotic depression . Modell JG . 9063050 . Psychiatry Online . https://wayback.archive-it.org/all/20080625161217/http://psy.psychiatryonline.org/cgi/reprint/38/2/160.pdf . dead . 2008-06-25 . 10.1016/S0033-3182(97)71493-2 . 2010-05-31 .
  20. Br J Clin Pharmacol . 1981 . 11 . Suppl 1 . 5S–9S . The use of benzodiazepines in clinical practice . Shader RI . Greenblatt DJ . 6133535 . 1401641 . 10.1111/j.1365-2125.1981.tb01832.x.
  21. 7892364 . November 1994. Curran, Hv . Bond, A . O'Sullivan, G . Bruce, M . Marks, I . Lelliot, P . Shine, P . Lader, M . Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder. . 24 . 4 . 969–76 . 0033-2917 . Psychological Medicine . 10.1017/S0033291700029056 . 38165723 .
  22. Nirenberg MJ . Dopamine agonist withdrawal syndrome: implications for patient care . Drugs Aging . 30 . 8 . 587–92 . 2013 . 23686524 . 10.1007/s40266-013-0090-z . 207489653 .
  23. Rimondini R . Sommer WH . Dall'Olio R . Heilig M . March 2008 . Long-lasting tolerance following a history of dependence . Addict Biol . 13 . 1 . 26–30 . 17850416 . 10.1111/j.1369-1600.2007.00079.x. 22263141 .
  24. Ahveninen J . Jääskeläinen IP . Pekkonen E . Hallberg A . Hietanen M . Näätänen R . Sillanaukee P . June 8, 1999 . Post-withdrawal changes in middle-latency auditory evoked potentials in abstinent human alcoholics . Neurosci Lett . 268 . 2 . 57–60 . 10400077 . 10.1016/S0304-3940(99)00378-X. 8525967 .
  25. Kiefer F . Andersohn F . Jahn H . Wolf K . Raedler TJ . Wiedemann K . January 2002 . Involvement of plasma atrial natriuretic peptide in protracted alcohol withdrawal . . 105 . 1 . 65–70 . 12086228 . 10.1034/j.1600-0447.2002.0_011.x . 29059697 .
  26. Bruijnzeel AW. Gold MS . November 2005 . The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence . Brain Res Brain Res Rev . 49 . 3 . 505–28 . 16269317 . 10.1016/j.brainresrev.2005.01.007 . 27909100 .
  27. Hart. CL. Marvin. CB. Silver. R. Smith. EE. Is cognitive functioning impaired in methamphetamine users? A critical review.. Neuropsychopharmacology. Feb 2012. 37. 3. 586–608. 10.1038/npp.2011.276. 22089317 . 3260986.
  28. Salo. Ruth. Buonocore. Michael. Laemon. Martin. Extended findings of brain metabolite normalization in MA-dependent subjects across sustained abstinence: A proton MRS study. Drug and Alcohol Dependence. 2011-01-15. 113. 2–3. 133–138. 10.1016/j.drugalcdep.2010.07.015. 20739127. 3000435.
  29. Roberts AJ . Heyser CJ . Cole M . Griffin P . Koob GF . June 2000 . Excessive ethanol drinking following a history of dependence: animal model of allostasis . Neuropsychopharmacology . 22 . 6 . 581–94 . 10788758 . 10.1016/S0893-133X(99)00167-0. 24384085 .
  30. De Soto CB, O'Donnell WE, De Soto JL . October 1989 . Long-term recovery in alcoholics . Alcohol Clin Exp Res . 13 . 5 . 693–7 . 2688470 . 10.1111/j.1530-0277.1989.tb00406.x .
  31. L. Saxon . S. Borg . A. J. Hiltunen. amp . Reduction of aggression during benzodiazepine withdrawal: effects of flumazenil . . 96 . 2 . 148–151 . August 2010 . 10.1016/j.pbb.2010.04.023 . 20451546. 41351863 .
  32. Beleslin D . 1991 . [Modern drug therapy in alcoholism] . Med Pregl . 44 . 7–8 . 279–84 . 1806768 .
  33. Wilde MI . Wagstaff AJ . June 1997 . Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification . Drugs . 53 . 6 . 1038–53 . 9179530 . 10.2165/00003495-199753060-00008. 195691152 .
  34. Malcolm R . Myrick H . Brady KT . Ballenger JC . 2001 . Update on anticonvulsants for the treatment of alcohol withdrawal . Am J Addict . 10 Suppl . 16–23 . 11268817 . 10.1080/10550490150504100 . 1.
  35. Le Bon O . Murphy JR . Staner L . Hoffmann G . Kormoss N . Kentos M . Dupont P . Lion K . Pelc I . Verbanck P . August 2003 . Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations . J Clin Psychopharmacol . 23 . 4 . 377–83 . 12920414 . 10.1097/01.jcp.0000085411.08426.d3 . 33686593 .
  36. Mueller TI . Stout RL . Rudden S . Brown RA . Gordon A . Solomon DA . Recupero PR . February 1997 . A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence . Alcohol Clin Exp Res . 21 . 1 . 86–92 . 9046378 . 10.1111/j.1530-0277.1997.tb03733.x.
  37. Hori T . Komiyama T . Harada S . Matsumoto T . 2005 . [Treatment of substance dependence by a bio-cognitive model based on behavioral pharmacology] . Seishin Shinkeigaku Zasshi . 107 . 11 . 1147–58 . 16408423 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Post-acute-withdrawal syndrome".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.